The effectiveness of a Gilead Sciences Inc. GILD, +1.05% emergency treatment for COVID-19 could be hampered by other drugs that have been associated with treating the disease, the Food and Drug Administration warned late Monday. The agency said that remdesivir, a drug made by Gilead that recently gained an emergency use authorization from the FDA, could be adversely affected if combined with the drugs chloroquine phosphate or hydroxychloroquine sulfate. The FDA said that the latter two drugs could reduce the effectiveness of the Gilead drug. Earlier Monday, the FDA revoked its emergency use authorization for hydroxychloroquine and chloroquine. Gilead shares rose 0.1% after hours, following a 1.1% rise to close the regular session at $73.97.
Watch Brazilian carnivals live, discuss the next world conflict in the video chat or just enjoy fresh videos with funny cat talking - with Ulive.news you are at the center of any event! Ask a streamer to show what is happening from a different angle, to ask a question to eyewitnesses or to pay attention to an important detail. We will translate your message into 64 languages so that you can easily understand each other.